{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:16:35Z","timestamp":1790619395052,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1889,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"},{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1111\/jth.13768","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T11:00:27Z","timestamp":1499338827000},"page":"1747-1756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Preclinical safety and efficacy of andexanet alfa in animal models"],"prefix":"10.1016","volume":"15","author":[{"given":"G.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Hollenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hutchaleelaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Curnutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13768_bb0010","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.13768_bb0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13768_bb0020","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13768_bb0025","first-page":"111","article-title":"Prevention and treatment of venous thromboembolism\u2013International Consensus Statement","volume":"32","author":"Nicolaides","year":"2013","journal-title":"Int Angiol"},{"key":"10.1111\/jth.13768_bb0030","first-page":"69a","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.13768_bb0035","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non\u2010valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.13768_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.12107","article-title":"Guideline on the management of bleeding in patients on antithrombotic agents","volume":"160","author":"Makris","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13768_bb0045","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/clc.22037","article-title":"Emergency management of bleeding associated with old and new oral anticoagulants","volume":"35","author":"Peacock","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1111\/jth.13768_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1111\/jth.13768_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0038-1642443","article-title":"A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non\u2010occlusive deep vein thrombosis","volume":"71","author":"Hollenbach","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13768_bb0060","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jth.13768_bb0065","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet Alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13768_bb0070","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1111\/jth.13768_bb0075","first-page":"30","article-title":"A phase 2 randomized, double\u2010blind, placebo\u2010controlled trial of PRT064445, a novel, universal antidote for direct and indirect Factor Xa inhibitors","volume":"11","author":"Crowther","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13768_bb0080","first-page":"3636","article-title":"A phase 2 randomized, double\u2010blind, placebo\u2010controlled trial demonstrating reversal of rivaroxaban\u2010induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors","volume":"122","author":"Crowther","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/jth.13768_bb0085","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V78.2.364.364","article-title":"DEGR\u2010factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage","volume":"78","author":"Taylor","year":"1991","journal-title":"Blood"},{"key":"10.1111\/jth.13768_bb0090","first-page":"634","article-title":"Interaction of andexanet alfa, a universal antidote to fXA inhibitors, with tissue factor pathway inhibitor enhances reversal of fXA inhibitor\u2010induced anticoagulation","volume":"13","author":"Lu","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13768_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.3831.3831","article-title":"Andexanet alfa, a universal antidote under development for Factor Xa inhibitors, reverses rivaroxaban\u2010induced inhibition of thrombin generation initiated by the intrinsic coagulation pathway independent of TFPI","volume":"128","author":"Lu","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.13768_bb0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13768","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13768\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:16:43Z","timestamp":1761535003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622008601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1538783622008601"],"URL":"https:\/\/doi.org\/10.1111\/jth.13768","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical safety and efficacy of andexanet alfa in animal models","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}